Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$2.3 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 101.73% year-over-year to -$2.3, compared with a TTM value of -$3.75 through Sep 2025, down 101.59%, and an annual FY2024 reading of -$20.91, up 81.59% over the prior year.
  • EPS (Weighted Average and Diluted) was -$2.3 for Q3 2025 at Avalo Therapeutics, down from -$1.92 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $257.98 in Q4 2023 and bottomed at -$1059.6 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$63.6, with a median of -$1.92 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 130716.05% in 2022, then skyrocketed 594.15% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.81 in 2021, then tumbled by 130716.05% to -$1059.6 in 2022, then surged by 124.35% to $257.98 in 2023, then crashed by 99.33% to $1.72 in 2024, then crashed by 233.72% to -$2.3 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AVTX at -$2.3 in Q3 2025, -$1.92 in Q2 2025, and -$1.25 in Q1 2025.